Yumanity Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 8

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 11

  • Investments
  • 2

Yumanity Therapeutics General Information

Description

Developer of transformative brain-penetrating small molecule drugs designed for the treatment of neurodegenerative diseases caused by protein misfolding. The company is focused on the discovery and development of innovative, disease-modifying therapies for patients with Parkinson's disease and related disorders, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Acquirer
Former Stock Listing
YMTX
Corporate Office
  • 40 Guest Street
  • Suite 4410
  • Boston, MA 02135
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Yumanity Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Yumanity Therapeutics‘s full profile, request access.

Request a free trial

Yumanity Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of transformative brain-penetrating small molecule drugs designed for the treatment of neurodegenerative disea
Drug Discovery
Boston, MA
8 As of 2022
00.000
000000&0 00.000

000000

s nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderi
0000 000000000
Toronto, Canada
0 As of 0000
000.00
000000000 000.00

000000

tur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
0000000000000
Basking Ridge, NJ
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Yumanity Therapeutics Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ProMIS Neurosciences Corporation Toronto, Canada 0 000.00 000000000 000.00
Lisata Therapeutics Corporate Backed or Acquired Basking Ridge, NJ 00 00000 000000000 00000
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA 000 00000 000000000000 00000
Capricor Therapeutics Formerly VC-backed San Diego, CA 000 000.00 00000000 000.00
Bioasis Technologies Corporation New Haven, CT 0 00.000 000000&0
You’re viewing 5 of 43 competitors. Get the full list »

Yumanity Therapeutics Executive Team (13)

Name Title Board Seat Contact Info
N. Coles MD Chairman
You’re viewing 1 of 13 executive team members. Get the full list »

Yumanity Therapeutics Board Members (12)

Name Representing Role Since
0000000 00000 00.0 Self Board Member 000 0000
0. 00000 00 Self Chairman 000 0000
You’re viewing 2 of 12 board members. Get the full list »

Yumanity Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Yumanity Therapeutics Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Yumanity Therapeutics‘s full profile, request access.

Request a free trial

Yumanity Therapeutics Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Kineta 16-Dec-2022 0000000 00 Drug Discovery 0000000 0
Proteostasis Therapeutics 22-Dec-2020 Merger/Acquisition Drug Discovery 0000000 0
To view Yumanity Therapeutics’s complete acquisitions history, request access »

Yumanity Therapeutics FAQs

  • When was Yumanity Therapeutics founded?

    Yumanity Therapeutics was founded in 2014.

  • Who is the founder of Yumanity Therapeutics?

    Daniel Tardiff Ph.D, Vikram Khurana MD, Chee Chung Ph.D, and Susan Lindquist Ph.D are the founders of Yumanity Therapeutics.

  • Where is Yumanity Therapeutics headquartered?

    Yumanity Therapeutics is headquartered in Boston, MA.

  • What is the size of Yumanity Therapeutics?

    Yumanity Therapeutics has 8 total employees.

  • What industry is Yumanity Therapeutics in?

    Yumanity Therapeutics’s primary industry is Drug Discovery.

  • Is Yumanity Therapeutics a private or public company?

    Yumanity Therapeutics is a Private company.

  • What is Yumanity Therapeutics’s current revenue?

    The current revenue for Yumanity Therapeutics is 000000.

  • How much funding has Yumanity Therapeutics raised over time?

    Yumanity Therapeutics has raised $1.45B.

  • Who are Yumanity Therapeutics’s investors?

    Alexandria Venture Investments, Biogen, Dolby Family Ventures, Fidelity Management & Research, and Hercules Capital BDC are 5 of 10 investors who have invested in Yumanity Therapeutics.

  • Who are Yumanity Therapeutics’s competitors?

    ProMIS Neurosciences, Lisata Therapeutics, NGM Biopharmaceuticals, Capricor Therapeutics, and Bioasis Technologies are some of the 43 competitors of Yumanity Therapeutics.

  • When was Yumanity Therapeutics acquired?

    Yumanity Therapeutics was acquired on 16-Dec-2022.

  • Who acquired Yumanity Therapeutics?

    Yumanity Therapeutics was acquired by Kineta and DGP Company.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »